$PCH Token
Crypto meets AI-driven Drug Discovery
The $PCH TokenPowering the Future of AI-Driven Drug Discovery
The PCH token is the cornerstone of Pharmatech AI’s innovative ecosystem, designed to align community interests with the company’s success in revolutionizing AI-driven drug discovery, particularly in cannabinoid-based therapies.
With a fixed total supply of 1,000,000,000 tokens and no future inflation, PCH ensures scarcity and potential value appreciation through a robust buyback and burn strategy. As a utility token, PCH offers multiple functions: it enables investors to participate in revenue sharing, engage in governance, access exclusive platform features like IP and patent licensing, and earn staking rewards. Starting in 2027, Pharmatech AI anticipates substantial revenues from research monetization, with recurring platform subscription income from 2028. Seventy percent of platform fees will flow into a Revenue Pool, distributed quarterly in stablecoins to qualified stakers, with projected annual cash flows of $84 million by 2028.
The token’s deflationary mechanism, where 10% of net revenues are used to repurchase and burn tokens, reduces circulating supply, potentially increasing value. The Mecklenburg-Vorpommern research campus, with its 55 MWp photovoltaic system and scalable infrastructure, enhances profitability by reducing energy costs by up to 70%, supporting larger staking pools and buybacks. This unique combination of real-world utility, revenue sharing, and sustainability makes PCH an attractive investment for those interested in the future of precision medicine and AI-driven innovation.
Pharmatech AI’s PCH token offers investors a direct stake in the company’s financial success through a transparent revenue-sharing model and advanced staking opportunities.
From 2028, the company projects $120 million in annual platform revenue, including $100 million from monetizing AI-driven research results (e.g., IP licenses and collaborations) and $20 million from AI-MDIP platform subscriptions. Of this, 70% ($84 million) is allocated to a Revenue Pool for advanced stakers, distributed quarterly in stablecoins based on staked token amounts and lock-up durations. Stakers can boost their rewards with loyalty multipliers (e.g., 3x for 36-month locks) and lock bonuses (up to 200% for 24 months), maximizing returns. Additionally, a fixed 5% APR staking option provides flexibility.
The buyback and burn strategy, utilizing 10% of revenues, continuously reduces the token supply, with an estimated 48 million PCH (5% of total supply) burned annually at a $0.25 token price, fostering deflationary pressure. Supported by low operational costs at the sustainable Mecklenburg-Vorpommern campus, this model ensures high margins, larger staking rewards, and a self-reinforcing value cycle. For investors, PCH represents a unique opportunity to benefit from Pharmatech AI’s growth in the $137.72 billion drug discovery market and the $41.4 billion medical cannabis market by 2030, combining financial returns with impactful innovation.
PCH Highlights
PCH Token Utility
The PCH token is a utility token with a fixed supply of 1,000,000,000, designed to drive Pharmatech AI’s ecosystem by offering multiple investor benefits. Its primary utilities include: IP and Patent Licensing, where newly discovered molecules or prediction models are auctioned as NFT-like license tokens, with bids exclusively in PCH, creating high demand from pharma partners; Advanced Staking, allowing holders to lock PCH for 6 to 36 months to earn a share of the 70% Revenue Pool ($84 million annually by 2028) in stablecoins, with loyalty multipliers (e.g., 3x for 36 months) and lock bonuses (up to 200% for 24 months); Fixed APR Staking, offering a 5% APR for flexible staking without lock-up; Governance, where staked PCH grants voting rights in snapshot votes to influence platform decisions; and Community Rewards, allocating marketing ecosystem tokens for airdrops to active members. The token’s deflationary nature, driven by a buyback and burn strategy using 10% of revenues, reduces supply, potentially increasing value. Hosted on an EVM-compatible rollup (e.g., Arbitrum One), PCH ensures low-cost, secure transactions, making it a versatile and attractive investment vehicle.
Revenue Sharing
Pharmatech AI’s revenue-sharing model directly ties PCH token holders to the company’s financial success. Starting in 2027, substantial revenues from research monetization (e.g., IP licenses) are expected, with recurring platform subscription income from 2028, totaling $120 million annually ($100 million from research results and $20 million from AI-MDIP subscriptions). Seventy percent of platform fees ($84 million) are allocated to a Revenue Pool, distributed quarterly in stablecoins to advanced stakers who lock their PCH for 6 to 36 months. Rewards are proportional to the staked amount and enhanced by loyalty multipliers (1.2x for 6 months, up to 3x for 36 months) and lock bonuses (e.g., 75% for 12 months). For example, staking 100,000 PCH for 12 months yields 262,500 weighting points (100,000 × 1.5 × 1.75), significantly boosting payout shares. A 5% APR in PCH tokens is also provided, and automatic reinvestment options offer a 10% bonus for re-staking rewards. This model ensures stakers benefit linearly from platform growth, with transparency via on-chain tracking and Dune Analytics dashboards.
Buyback and Burn
The buyback and burn strategy is a core deflationary mechanism for PCH, reducing the circulating supply to enhance token value. Ten percent of net platform revenues (e.g., $12 million from a $120 million annual revenue) are automatically allocated to a Buy Back Wallet. This wallet executes a time-weighted Dollar-Cost Averaging (DCA) strategy to repurchase PCH tokens from the market, minimizing market impact by adhering to a predefined slippage threshold. Purchased tokens are sent to a “Black Hole” address, permanently removing them from circulation, as no protocol or multisig can access the burn wallet. For instance, at a $0.25 token price, $12 million could burn 48 million PCH annually, roughly 5% of the total supply. This process is transparent, with on-chain events logging timestamps, quantities, and average prices, trackable via Dune Analytics. The strategy operates alongside the 70/10/20 cash flow split (70% Revenue Pool, 10% buyback, 20% operations/CAPEX), ensuring staking rewards and expansion budgets remain unaffected, creating a positive feedback loop of higher revenues, larger burns, and increased token scarcity.
Staking Rewards
PCH token holders can earn rewards through two staking models: Baseline Stake and Advanced Staking. The Baseline Stake allows flexible staking without lock-up, offering a 5% APR in PCH tokens, sourced from the Treasury. Advanced Staking requires locking tokens for 6, 12, 24, or 36 months, qualifying holders for a share of the Revenue Pool (70% of platform fees, $84 million annually by 2028) in stablecoins. Rewards are enhanced by loyalty multipliers (e.g., 1.5x for 12 months, 3x for 36 months) and immediate lock bonuses (e.g., 75% for 12 months, 200% for 24 months). For example, locking 100,000 PCH for 12 months generates 262,500 weighting points, significantly increasing payout shares. Staking includes a 2–4 week Cool Off period before rewards begin and a Cool Down period upon unstaking, with early exits within six months forfeiting bonus rewards to incentivize long-term commitment. Additional features include automatic reward reinvestment with a 10% bonus, flexible lock-up upgrades, and gamification elements like status levels (Bronze to Platinum) and community challenges, making staking both lucrative and engaging.
Token Distribution
The PCH token has a fixed supply of 1,000,000,000, allocated as follows: Core Team (8%, 80M), Advisors (3%, 30M), Pre-Seed (4%, 40M), Seed (6%, 60M), KOL Round (4%, 40M), Public Round (7%, 70M), Partnerships/Development (10%, 100M), Marketing Ecosystem (15%, 150M), and Treasury/Liquidity Pool (43%, 430M). Fundraising phases raised $4.745 million, with token prices from $0.0135 (Pre-Seed) to $0.0325 (Public Round), launching at $0.0325 for a fully diluted market cap of $32.5 million. Vesting schedules ensure long-term alignment: Core Team (0% at TGE, 12-month cliff, 36-month linear release), Advisors (0% at TGE, 6-month cliff, 12-month linear), Pre-Seed (0% at TGE, 2-month cliff, 12-month linear), Seed (5% at TGE, 1-month cliff, 12-month linear), KOL Round (10% at TGE, 12-month linear), Public Round (15% at TGE, 12-month linear), Partnerships (3% at TGE, 12-month linear), Marketing (5% at TGE, 12-month linear), and Treasury (40% at TGE, 12-month linear). This structure balances immediate liquidity with long-term commitment, fostering investor confidence and ecosystem stability.
“In drug discovery, AI is the key to unlocking new therapies, and crypto is the currency that fuels the revolution.”
Mert Enginer, Data Center Infrastructure Manager